Spyre Therapeutics Completes Recruitment for RA Sub-Study of SKYWAY Trial
Spyre Therapeutics announced the completion of recruitment for the RA sub-study of the SKYWAY basket trial and acceleration of expected topline readout to Q3 2026. "Enrollment in the RA sub-study of SKYWAY has exceeded our expectations and reflects both substantial unmet need as well as investigator enthusiasm for the potential of a long-acting anti-TL1A antibody," said Joshua Friedman, M.D., Ph.D., SVP of Clinical Development and SKYWAY study lead. "We look forward to delivering the first proof-of-concept data for this mechanism in rheumatic disease in the third quarter, with the potential to advance to pivotal trials next year. Together with readouts from the SKYLINE study, we now expect key data from Spyre's programs in IBD and rheumatic diseases in every subsequent quarter this year."
